| 杨东 孙宏伟 郑志超 赵岩 秦宝丽.血小板生成素与白介素-11 治疗胃癌术后辅助化疗后血小板减少症时效
及安全性的比较[J].现代生物医学进展英文版,2015,15(22):4326-4329. |
| 血小板生成素与白介素-11 治疗胃癌术后辅助化疗后血小板减少症时效
及安全性的比较 |
| Compared Effect and Safety of Thrombopoietin and Interleukin -11 inTreatment of Platelet Reduce of Gastric Cancer Patients after PostoperativeAdjuvant Chemotherapy |
| |
| DOI： |
| 中文关键词: 重组人血小板生成素 重组人白介素-11 血小板减少症 胃癌 化学治疗 |
| 英文关键词: Recombinant human thrombopoietin Recombinant human interleukin-11 Thrombocytopenia stomach neoplasms Chemotherapy |
| 基金项目:辽宁省科技专项基金项目（2012225016） |
|
| Hits: 793 |
| Download times: 0 |
| 中文摘要: |
| 目的：比较血小板生成素与白介素-11 治疗胃癌患者术后化疗血小板减少症的时效和安全性。方法：术后辅助化疗出现血小
板计数低于75× 109/L的进展期胃癌患者68 例，将其分为TPO 组与IL-11 组，分别为35 例和33 例。分别皮下注射rhTPO 15000
U，每日1 次；rhIL-11 1.5 mg，每日1 次，当血小板计数>125× 109/L 或比用药前上升50× 109/ L，即停止给药，疗程最长为14 天。
每3 天抽取外周静脉血2 mL，通过全自动血液分析仪测定血小板计数，密切观察出现的不良反应并记录。比较两组患者不同临床
病理资料、血小板计数、血小板计数升至75× 109/L和125× 109/L的时程、药物不良反应。结果：两组患者年龄、性别、化疗方案、血
小板最低值出现的化疗周期及临床病理分期的比较均没有统计学差异（P 值均>0.05）。TPO组与IL-11 组血小板动态值的比较，
第9 天出现显著差异(P=0.032）。TPO 组与IL-11 组血小板计数恢复至75× 109 /L 和125× 109 /L 所需的时间，有显著差异（P=0.
041，P=0.013）。TPO 组中，有3 例(8.6%)患者发生不良反应，IL-11组中，有13例(39.4%)患者发生不良反应，TPO 组患者出现的不
良反应少且较轻微（P=0.006）。结论：rhTPO 治疗胃癌患者术后化疗血小板减少症时效快，安全性好。 |
| 英文摘要: |
| Objective:To compared the effect and safety of recombinant human interleukin -11 and recombinant human
thrombopoietin in treatment of gastric cancer thrombocytopenia after chemotherapy.Methods:There were 68 cases gastric cancer patients
receiving postoperative adjuvant chemotherapy with their platelet counts of lower than 75× 109/L, who were divided into TPO group (35
cases) and IL-11 group (33 cases). They were given subcutaneous injection of 15000U rhTPO or 1.5 mg rhIL-11, once daily. The
treatment duration was 7~14 days. In case the platelet counts surpass 125× 109/L or an absolute count increase of 50*109/L, the treatment
was terminated. Otherwise, the treatment continued for 2 weeks. Platelet counts were monitored by a 3-day's interval. The adverse
reaction was carefully recorded. We compared the dynamic platelet count, the time of platelet count to 75× 109/L and 125× 109/L, and
adverse effects after treatment between the 2 groups.Results:Clinicopathological data and chemotherapeutic regimens were well
balanced between the 2 groups (P>0.05). The platelet counts in the 9th day of the TPO group was significantly higher than IL-11 group
(P=0.032). The time of platelet counts raised to 75× 109/L and 125× 109/L was significantly faster in TPO group than IL-11 group (P=0.
041, P=0.013). We observed 3 cases (8.6%) of side reactions in TPO group and 13 cases (39.4%) in IL-11 group, which is statistically
different (P=0.006).Conclusion:To treat the chemotherapy induced thrombocytopenia in gastric cancer patients receiving postoperative
chemotherapy, rhTPO was a better choice for its efficiency and safety comparing to rhIL-11. |
|
View Full Text
View/Add Comment Download reader |
| Close |
